Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- April15 2004
- Volume 11
- Issue 7
Big Bucks in Lobbying
Advertisement
National Journal
Doctors know that when it comes to compensation, times are very tough. The average primary care physician faces annual income increases that fail to top inflation. How are those in the health care–influencing profession faring in the payday department? Not too shabbily. The median is about $318,000, according to the seventh (www.nationaljournal.com) compensation survey of "Washington's associations, think tanks, labor unions, and interest groups":
Articles in this issue
about 18 years ago
Preserve Peace of Mind with a Stable Insurance Planabout 18 years ago
Bizarre Insurance Policiesabout 18 years ago
Live Longer and Save on Life Insuranceabout 18 years ago
Pay Attention to Fund Brokerage Costsabout 18 years ago
Critique Your Favorite Fund Columnistabout 18 years ago
Discover the Advantages of Small Fundsabout 18 years ago
Watch Out for the Plummeting US Dollarabout 18 years ago
Take Note from Bad Big Name Stock Dealsabout 18 years ago
Model Portfolio Series: Aggressive Growthabout 18 years ago
Does Today's Good Life Grief Hit Home?Advertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5